In clinical trials, participants reported eating 30 to 50% less than their pre treatment amounts without conscious effort
expression has been also reported in other tissues such as the kidney, lung, placenta, and heart (Zhang et al., 2010)
Furthermore, there has been an indication of tirzepatide reducing liver fat, and improving nephrotic outcomes as evidenced by the lower urine albumin: creatinine ratio and the slower decline of estimated glomerular filtration rate in people with T2DM [56]
Timing of administration is flexible
This is the latest reported benefit of GLP1s, originally prescribed for diabetes management and now prescribed widely for obesity
Note: The above statements have not been evaluated by the Food and Drug Administration